Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANATEE: RO7204239 plus risdiplam in spinal muscular atrophy
NL-OMON59136Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal muscular atrophy (SMA) comparing RO7204239 + risdiplam with Placebo + risdiplam (2 arms). Primary endpoints: Incidence, severity, and causal relationship of adverse events, Change from baseline in safety assessments and 19 more. Started Jul 2022; status: completed.
02
Drugs
emugrobartrisdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON59136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59136.